纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤 - Suppr

Suppr

超能文献

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

作者信息

Valsecchi Matias E

出版信息

N Engl J Med. 2015 Sep 24;373(13):1270. doi: 10.1056/NEJMc1509660.

DOI:10.1056/NEJMc1509660

PMID:26398077

Abstract

摘要

相似文献

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med. 2015 Sep 24;373(13):1270. doi: 10.1056/NEJMc1509660.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med. 2015 Sep 24;373(13):1270-1. doi: 10.1056/NEJMc1509660.

Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.

Nat Rev Clin Oncol. 2015 Aug;12(8):435. doi: 10.1038/nrclinonc.2015.112. Epub 2015 Jun 23.

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20.

Nivolumab in melanoma.

Expert Rev Anticancer Ther. 2016 Dec;16(12):1247-1261. doi: 10.1080/14737140.2016.1249856. Epub 2016 Nov 7.

The role of nivolumab in melanoma.

Future Oncol. 2018 Jun;14(13):1241-1252. doi: 10.2217/fon-2017-0484. Epub 2018 Jan 12.

Nivolumab: A Review in Advanced Melanoma.

Drugs. 2015 Aug;75(12):1413-24. doi: 10.1007/s40265-015-0442-6.

Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.

J Dermatol Sci. 2018 Jan;89(1):60-66. doi: 10.1016/j.jdermsci.2017.10.009. Epub 2017 Oct 25.

Nivolumab + ipilimumab ups melanoma response.

Cancer Discov. 2015 Jun;5(6):OF2. doi: 10.1158/2159-8290.CD-NB2015-058. Epub 2015 Apr 21.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

引用本文的文献

Bispecific antibody for lung cancer: mechanisms and clinical insights.

Front Immunol. 2025 May 29;16:1572802. doi: 10.3389/fimmu.2025.1572802. eCollection 2025.

Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis.

J Gastrointest Cancer. 2025 Apr 1;56(1):90. doi: 10.1007/s12029-025-01215-x.

Turning "trashed" genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells.

Mol Ther. 2025 Apr 2;33(4):1368-1379. doi: 10.1016/j.ymthe.2025.02.028. Epub 2025 Feb 20.

CD4+ T helper 2 cell-macrophage crosstalk induces IL-24-mediated breast cancer suppression.

JCI Insight. 2025 Jan 9;10(1):e180962. doi: 10.1172/jci.insight.180962.

Novel research model for in vitro immunotherapy: co-culturing tumor organoids with peripheral blood mononuclear cells.

Cancer Cell Int. 2024 Dec 31;24(1):438. doi: 10.1186/s12935-024-03628-3.

Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.

Heliyon. 2024 Oct 5;10(20):e38888. doi: 10.1016/j.heliyon.2024.e38888. eCollection 2024 Oct 30.

Research progress and challenges of the PD-1/PD-L1 axis in gliomas.

Cell Biosci. 2024 Sep 27;14(1):123. doi: 10.1186/s13578-024-01305-6.

Toxicity in the era of immune checkpoint inhibitor therapy.

Front Immunol. 2024 Aug 23;15:1447021. doi: 10.3389/fimmu.2024.1447021. eCollection 2024.

De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.

Cancer Res Commun. 2024 May 2;4(5):1174-1188. doi: 10.1158/2767-9764.CRC-23-0450.

Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.

Signal Transduct Target Ther. 2024 Apr 3;9(1):83. doi: 10.1038/s41392-024-01779-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med. 2015 Sep 24;373(13):1270. doi: 10.1056/NEJMc1509660.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med. 2015 Sep 24;373(13):1270-1. doi: 10.1056/NEJMc1509660.

Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.

Nat Rev Clin Oncol. 2015 Aug;12(8):435. doi: 10.1038/nrclinonc.2015.112. Epub 2015 Jun 23.

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20.

Nivolumab in melanoma.

Expert Rev Anticancer Ther. 2016 Dec;16(12):1247-1261. doi: 10.1080/14737140.2016.1249856. Epub 2016 Nov 7.

The role of nivolumab in melanoma.

Future Oncol. 2018 Jun;14(13):1241-1252. doi: 10.2217/fon-2017-0484. Epub 2018 Jan 12.

Nivolumab: A Review in Advanced Melanoma.

Drugs. 2015 Aug;75(12):1413-24. doi: 10.1007/s40265-015-0442-6.

Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.

J Dermatol Sci. 2018 Jan;89(1):60-66. doi: 10.1016/j.jdermsci.2017.10.009. Epub 2017 Oct 25.

Nivolumab + ipilimumab ups melanoma response.

Cancer Discov. 2015 Jun;5(6):OF2. doi: 10.1158/2159-8290.CD-NB2015-058. Epub 2015 Apr 21.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

引用本文的文献

Bispecific antibody for lung cancer: mechanisms and clinical insights.

Front Immunol. 2025 May 29;16:1572802. doi: 10.3389/fimmu.2025.1572802. eCollection 2025.

Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis.

J Gastrointest Cancer. 2025 Apr 1;56(1):90. doi: 10.1007/s12029-025-01215-x.

Turning "trashed" genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells.

Mol Ther. 2025 Apr 2;33(4):1368-1379. doi: 10.1016/j.ymthe.2025.02.028. Epub 2025 Feb 20.

CD4+ T helper 2 cell-macrophage crosstalk induces IL-24-mediated breast cancer suppression.

JCI Insight. 2025 Jan 9;10(1):e180962. doi: 10.1172/jci.insight.180962.

Novel research model for in vitro immunotherapy: co-culturing tumor organoids with peripheral blood mononuclear cells.

Cancer Cell Int. 2024 Dec 31;24(1):438. doi: 10.1186/s12935-024-03628-3.

Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.

Heliyon. 2024 Oct 5;10(20):e38888. doi: 10.1016/j.heliyon.2024.e38888. eCollection 2024 Oct 30.

Research progress and challenges of the PD-1/PD-L1 axis in gliomas.

Cell Biosci. 2024 Sep 27;14(1):123. doi: 10.1186/s13578-024-01305-6.

Toxicity in the era of immune checkpoint inhibitor therapy.

Front Immunol. 2024 Aug 23;15:1447021. doi: 10.3389/fimmu.2024.1447021. eCollection 2024.

De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.

Cancer Res Commun. 2024 May 2;4(5):1174-1188. doi: 10.1158/2767-9764.CRC-23-0450.

Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.

Signal Transduct Target Ther. 2024 Apr 3;9(1):83. doi: 10.1038/s41392-024-01779-3.